Loading...
Loading...
China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc.. Spoken Alpha tracks SXTC's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks SXTC's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 80% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SXTC.
curl https://api.spokenalpha.com/v1/companies/SXTC| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.77 | $2.18 | +27.0% | +2.6% | +1.5% |
| Q4 FY2026 | $2.71 | $1.93 | +40.3% | +3.2% | +1.0% |
| Q3 FY2026 | $2.64 | $2.09 | +26.4% | +1.6% | +1.8% |
| Q2 FY2026 | $2.77 | $2.02 | +37.0% | -0.6% | -1.6% |
| Q1 FY2025 | $2.70 | $2.04 | +32.3% | +6.5% | +8.0% |
| Q4 FY2025 | $3.10 | $2.28 | +35.9% | +5.1% | +6.1% |
| Q3 FY2025 | $3.03 | $2.15 | +41.1% | +6.4% | +7.7% |
| Q2 FY2025 | $3.21 | $2.27 | +41.2% | +2.5% | +2.9% |
| Q1 FY2024 | $3.28 | $2.33 | +40.8% | -1.2% | -1.3% |
| Q4 FY2024 | $3.08 | $2.34 | +31.5% | +0.4% | +0.1% |